Author Index to Volume 49

Abel L. See Schröder J
Abelson JL, Weg JG, Nesse RM, Curtis GC. Persistent respiratory irregularity in patients with panic disorder, 588
Abukneil SS. See Lawrie SM
Adolfsson R. See Souery D
Adson DE. See Kim SW
Al-Amin HA, Weickert CS, Weinberger DR, Lipska BK. Delayed onset of enhanced MK-801-induced motor hyperactivity after neonatal lesions of the rat ventral hippocampus, 528
Albuquerque EX. See Maelicke A
Allen G. See Müller R-A
Allen PB. See Lidow MS
Allen YS. See Zamani MR
Alvir J. See Lieberman J
Amador XF. See Kayser J
Ambrose JB. See Müller R-A
Andreasen NC. See Miller DD
Andreasen NC. See Nopoulos PC
Andrew R. See Rasmuson S
Arndt S. See Coryell W
Asarnow JR. See Wells KB
Asenbaum S. See Tauscher J
Assies J, Lieverse R, Vreken P, Wanders RJA, Dingemans PMJA, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group, 510
Avenevoli S. See Kessler RC
Avenevoli S, Stolar M, Li J, Dierker L, Merikangas KR. Comorbidity of depression in children and adolescents: models and evidence from a prospective high-risk family study, 1071

Babulas V. See Brown AS
Baek D. See Ruskin DN
Bailer U. See Tauscher J
Ballard C. See O'Brien J
Barr CL, Xu C, Kroft J, Feng Y, Wigg K, Zai G, Tannock R, Schachar R, Malone M, Roberts W, Nöthen MM, Grünhage F, Vandenbergh DJ, Uhl G, Sunohara G, King N, Kennedy JL. Haplotype study of three polymorphisms at the dopamine transporter locus confirm linkage to attention-deficit/hyperactivity disorder, 333
Beardslee WR, Gladstone TRG. Prevention of childhood depression: recent findings and future prospects, 1101
Begleiter H. See Hada M
Bejerot S. See Humble M
Bengtsson F. See Humble M
Benson BE. See Ketter TA
Bergqvist PBF. See Humble M
Bergstrom DA. See Ruskin DN
Berman R. See Boutros NN
Bertolino A, Callicott JH, Mattay VS, Weidenhammer KM, Rakow R, Egan MF, Weinberger DR. The effect of treatment with antipsychotic drugs on brain *N*-acetylaspartate measures in patients with schizophrenia, 39
Best JJK. See Lawrie SM
Biederman J. See Spencer TJ
Bilder R. See Lieberman J
Birkett MA. See Tollefson GD
Blackwood D. See Souery D
Blairy S. See Souery D
Boada F. See Soares JC
Bodner SM, Morshed SA, Peterson BS. The question of PANDAS in adults, 807
Bohning DE. See McConnell KA
Boles Ponto LL. See Miller DD
Boutros NN, Lisanby SH, Tokuno H, Torello MW, Campbell D, Berman R, Malison R, Krystal JH, Kosten T. Elevated motor threshold in drug-free, cocaine-dependent patients assessed with transcranial magnetic stimulation, 369
Bouwknecht JA, Hijzen TH, van der Gugten J, Maes RAA, Hen R, Olivier, B. Absence of 5-HT_{1B} receptors is associated with impaired impulse control in male 5-HT_{1B} knockout mice, 557
Braff DL. See Green MF
Braff DL. See Paulus MP
Breiter HC. See Elman I
Brown A. See O'Brien J
Brown AS, Cohen P, Harkavy-Friedman J, Babulas V, Malaspina D, Gorman JM, Susser ES. Prenatal rubella, premorbid abnormalities, and adult schizophrenia, 473
Brown GM. See Fu CHY
Brücke T. See Tauscher J
Bruder GE. See Kayser J
Bruder GE, Stewart JW, Tenke CE, McGrath PJ, Leite P, Bhattacharya N, Quitkin FM. Electroencephalographic and perceptual asymmetry differences between responders and nonresponders to an SSRI antidepressant, 416
Buchsbaum MS. See Schröder J
Burnette CP. See Kates WR
Buse DC. See Lindamer LA
Bymaster FP. See Perry KW

Callicott JH. See Bertolino A
Campbell D. See Boutros NN
Carlsson A. See Kegeles LS
Casper RC, Tollefson GD, Nilsson ME. No gender differences in placebo responses of patients with major depressive disorder, 158
Castner SA. See Lidow MS
Ceilley JW. See Nopoulos PC
Chahl LA. See Tooney PA
Chakos M. See Lieberman J
Chang K-A. See Seo J-H
Charney DS. See Kaufman J
Charney DS. See Oren DA
Charney DS. See Woods SW
Chen AC-H, Shirayama Y, Shin K-H, Neve RL, Duman RS. Expression of the cAMP response element binding protein (CREB) in hippocampus produces an antidepressant effect, 753

Abbreviations:
ed: editorial
cor: correspondence.

© 2001 Society of Biological Psychiatry

0006-3223/01/$20.00
PII S0006-3223(01)01194-5

Choi SH. See Seo J-H
Chorlian DB. See Hada M
Ciaravolo TM. See Schröder J
Cohen BM. See Kaufman MJ
Cohen P. See Brown AS
Cohen R. See Rockstroh B
Conwell Y. See Rubio A
Coplan JD. See Goetz RR
Corwin J. See Newhouse PA
Coryell W, Fyer A, Pine D, Martinez J, Arndt S. Aberrant respiratory sensitivity to CO_2 as a trait of familial panic disorder, 582
Courchesne E. See Müller R-A
Courchesne E. See Pierce K
Court J, Martin-Ruiz C, Piggott M, Spurden D, Griffiths M, Perry E. Nicotinic receptor abnormalities in Alzheimer's disease, 175
Cox C. See Rubio A
Coyle JT. Childhood mood disorders: unmet needs but important opportunities, 959-ed
Coyle JT, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer's disease, 289
Crawter VC. See Tooney PA
Curry JF. Specific psychotherapies for childhood and adolescent depression, 1091
Curtis GC. See Abelson JL

Dager SR. See Strauss WL
Dahl RE. See Thomas KM
Dani, JA. Overview of nicotinic receptors and their roles in the central nervous system, 166
Danielson A. See Ketter TA
David AS.. See Shapleske J
Davis KL. See Schröder J
Davis KL. Nicotinic mechanisms: potential for therapeutic exploitation, 165-ed
De Bellis MD. See Hill SY
Deep D. See Kaye WH
Del-Favero J. See Souery D
de Zwaan M. See Tauscher J
Dierker L. See Avenevoli S
Dikeos D. See Souery D
Ding Y-S. See Volkow ND
Dingemans PMJA. See Assies J
Dippold CS. See Soares JC
Dolberg OT, Schreiber S, Grunhaus L. Transcranial magnetic stimulation-induced switch into mania: a report of two cases, 468
Domino EF. See Zubieta J-K
Donnelly L. See Lawrie SM
Dostal K. See Kaufman MJ
Drevets WC. See Thomas KM
Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, Price JL, Mathis CA. Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria, 82
Duman RS. See Chen AC-H
Dunn RT. See Ketter TA

Eaves L. See Silberg JL
Eccard CH. See Thomas KM
Egan MF. See Bertolino A
Eisfeld BS. See Fu CHY
Elbert T. See Rockstroh B
Eliez S, Schmitt JE, White CD, Wellis VG, Reiss AL. A quantitative MRI study of posterior fossa development in velocardiofacial syndrome, 540
Elman I, Krause S, Karlsgodt K, Schoenfeld DA, Gollub RL, Breiter HC, Gastfriend DR. Clinical outcomes following cocaine infusion in non-treatment seeking individuals with cocaine dependence, 553
Elsayed H. See Loo C
Emslie GJ, Mayes TL. Mood disorders in children and adolescents: psychopharmacological treatment, 1082
Enoch M-A, Greenberg BD, Murphy DL, Goldman D. Sexually dimorphic relationship of a 5-HT_{2A} promoter polymorphism with obsessive-compulsive disorder, 385
Eulitz C. See Rockstroh B

Faraone SV. See Spencer TJ
Fehrenbacher A. See Maelicke A
Felder CC. See Perry KW
Feng Y. See Barr CL
Ferrier N. See O'Brien J
Finlay JM. See Jedema HP
Forbes NT. See Rubio A
Ford JM, Mathalon DH, Kalba S, Marsh L, Pfefferbaum A. N1 and P300 abnormalities in patients with schizophrenia, epilepsy, and epilepsy with schizophrenialike features, 848
Fost N. Ethical issues in research and innovative therapy in children with mood disorders, 1015
Fowler JS. See Volkow ND
Frangou S. See Matsumoto H
Frank E. See Soares JC
Freeman LE. See Ruskin DN
Freidland RP. See Zeng H
Frey K. See Lahti AC
Frey KA. See Zubieta J-K
Friedman L. See Konick LC
Friedman L. Why vote-count reviews don't count, 161-corr
Frumin M. See McCarley RW
Frye MA. See Ketter TA
Fu CHY, Reed LJ, Meyer JH, Kennedy S, Houle S, Eisfeld BS. Brown GM. Noradrenergic dysfunction in the prefrontal cortex in depression: an [^{15}O] H_2O PET study of the neuromodulatory effects of clonidine, 317
Fyer A. See Coryell W

Gailis ES. See Nopoulos PC
Gainski J. See Gurrera RJ
Gandevia S. See Loo C
Gastfriend DR. See Elman I
Gatley SJ. See Volkow ND
Gautier C. See Drevets WC
George CA. See Perry KW
George MS. See Ketter TA
George MS. See McConnell KA
George TP, Picciotto MR, Verrico CD, Roth RH. Effects of nicotine pretreatment on dopaminergic and behavioral responses to conditioned fear stress in rats: dissociation of biochemical and behavioral effects, 300
Geppert C. See Roberts LW
Geraghty M. See Kates WR
Germain A. See Krakow B
Gershenfeld HK. See Liu X
Gershon S. See Pettegrew JW
Gershon S. See Soares JC
Girdler SS, Straneva PA, Light KC, Pedersen CA, Morrow AL. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder, 788
Gladstone TRG. See Beardslee WR
Glied S, Neufeld A. Service system finance: implications for children with depression and manic depression, 1128

Goetz RR, Wolk SI, Coplan JD, Ryan ND, Weissman MM. Premorbid polysomnographic signs in depressed adolescents: a reanalysis of EEG sleep after longitudinal follow-up in adulthood, 930
Goldman D. See Enoch M-A
Goldman-Rakic PS. See Lidow MS
Gollub RL. See Elman I
Goodwin GM. See McCleery JM
Gorman JM. See Brown AS
Gorman JM. See Kayser J
Grace AA. See Drevets WC
Grace AA. See Jedema HP
Grados M. See Kates WR
Granholm E. See Siegle GJ
Grant JE. See Kim SW
Grant MM, Weiss JM. Effects of chronic antidepressant drug administration and electroconvulsive shock on locus coeruleus electrophysiologic activity, 117
Green MF, Braff DL. Translating the basic and clinical cognitive neuroscience of schizophrenia to drug development and clinical trials of antipsychotic medications, 374
Greenberg BD. See Enoch M-A
Greengard P. See Lidow MS
Griffiths M. See Court J
Groenink L. See Pattij, T
Grünhage F, See Barr CL
Grunhaus L. See Dolberg OT
Gurrera RJ, O'Donnell BF, Nestor PG, Gainski J, McCarley RW. The P3 auditory event-related brain potential indexes major personality traits, 922
Guthrie S. See Zubieta J-K
Gutman D. See Lisanby SH
Gutman DA. See Rilling JK

Hada M, Porjesz B, Chorlian DB, Begleiter H, Polich J. Auditory P3a deficits in male subjects at high risk for alcoholism, 726
Halaris A. See Rajkowska G
Hall J. See Hill SY
Harkavy-Friedman J. See Brown AS
Hazlett EA. See Schröder J
Heim C, Nemeroff CB. The role of childhood trauma in the neurobiology of mood and anxiety disorders: preclinical and clinical studies, 1023
Hen R. See Bouwknecht JA
Hen R. See Pattij, T
Heresco-Levy U. See Shoham S
Herscovitch P. See Ketter TA
Hichwa ED. See Miller DD
Hijzen TH. See Bouwknecht JA
Hijzen TH. See Pattij, T
Hill SY, De Bellis MD, Keshavan MS, Lowers L, Shen S, Hall J, Pitts T. Right amygdala volume in adolescent and young adult offspring from families at high risk for developing alcoholism, 894
Hirayasu Y. See McCarley RW
Hoffman E. See Lieberman J
Hoffman JM. See Rilling JK
Hoffman RE, Quinlan DM, Mazure CM, McGlashan TM. Cortical instability and the mechanism of mania: a neural network simulation and perceptual test, 500
Hollifield M. See Krakow B
Holzbach R. See Kiefer F
Honda M, Honda Y, Uchida S, Miyazaki S, Tokunaga K. Monozygotic twins incompletely concordant for narcolepsy, 943
Honda Y. See Honda M
Houle S. See Fu CHY
Hsu LKG. See Kaye WH
Huguelet P. See Zubieta J-K
Humble M, Bejerot S, Bergqvist PBF, Bengtsson F. Reactivity of serotonin in whole blood: relationship with drug response in obsessive-compulsive disorder, 360
Hyman SE. Mood disorders in children and adolescents: an NIMH perspective, 962

Ichimiya T, Okubo Y, Suhara T, Sudo Y. Reduced volume of the cerebellar vermis in neuroleptic-naive schizophrenia, 20
Ingram RE. See Siegle GJ

Jabs EW. See Kates WR
Jahn H. See Kiefer F
Jakovljevic M. See Souery D
Jaros E. See O'Brien J
Jaschinski M. See Kiefer F
Javitt DC. See Shoham S
Jedema HP, Finlay JM, Sved AF, Grace AA. Chronic cold exposure potentiates CRH-evoked increases in electrophysiologic activity of locus coeruleus neurons, 351
Jeong S-J. See Seo J-H
Jeste DV. See Lindamer LA
Johnston L. See Krakow B
Johnstone EC. See Lawrie SM
Jostock R. See Maelicke A

Kagan J. The unmet needs in diagnosis and treatment of mood disorders in children and adolescents, 973
Kalba S. See Ford JM
Kaneva R. See Souery D
Kapur S, Seeman P. Ketamine, NMDA, and dopamine D_2 receptor, 954-corr
Karlsgodt K. See Elman I
Kasper S. See Tauscher J
Kataoka SH. See Wells KB
Kates WR, Burnette CP, Jabs EW, Rutberg J, Murphy AM, Grados M, Geraghty M, Kaufman WE, Pearlson GD. Regional cortical white matter reductions in velocardiofacial syndrome: a volumetric MRI analysis, 677
Kaufman J, Martin A, King RA, Charney D. Are child-, adolescent-, and adult-onset depression one and the same disorder?, 980
Kaufman MJ, Levin JM, Maas LC, Kukes TJ, Villafuerte RA, Dostal K, Lukas SE, Mendelson JH, Cohen BM, Renshaw PF. Cocaine-induced cerebral vasoconstriction differs as a function of gender and menstrual cycle phase, 774
Kaufman WE. See Kates WR
Kaye WH, Nagata T, Weltzin TE, Hsu LKG, Sokol MS, McConaha C, Plotnicov KH, Weise J, Deep D. Double-blind placebo-controlled administration of fluoxetine in restricting- and restricting-purging-type anorexia nervosa, 644
Kayser J, Bruder GE, Tenke CE, Stuart BK, Amador XF, Gorman JM. Event-related brain potentials (ERPs) in schizophrenia for tonal and phonetic oddball tasks, 832
Kegeles LS, Laruelle M, Carlsson A. Ketamine, NMDA, and dopamine D_1 receptor, 955-corr (response)
Keith SJ. See Roberts LW
Kelton M. See Newhouse PA
Kennedy JL. See Barr CL
Kennedy S. See Fu CHY
Kershaw P. See Coyle J
Keshavan MS. See Hill SY
Keshavan MS. See Soares JC

Kessler RC. Avenevoli S, Merikangas KR. Mood disorders in children and adolescents: an epidemiologic perspective, 1002
Kestelman JN. See Lawrie SM
Ketter TA, Kimbrell TA, George MS, Dunn RT, Speer AM, Benson BE, Willis MW, Danielson A, Frye MA, Herscovitch P, Post RM. Effects of mood and subtype on cerebral glucose metabolism in treatment-resistant bipolar disorder, 97
Kiefer F, Jahn H, Jaschinski M, Holzbach R, Wolf K, Naber D, Wiedemann K. Leptin: a modulator of alcohol craving?
Kiesler GM. See Tollefson GD
Kihara T. See Shimohama S
Kilbourn MR. See Zubieta J-K
Kilts CD. See Rilling JK
Kim E-M. See Seo J-H
Kim H-S. See Seo J-H
Kim S-H. See Seo J-H
Kim SW, Grant JE, Adson DE, Shin YC. Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling, 914
Kimbrell TA. See Ketter TA
Kinahan PE. See Drevets WC
King N. See Barr CL
King RA. See Kaufman J
Kissler J. See Rockstroh B
Koeppe RA. See Zubieta J-K
Konick LC, Friedman L. Meta-analysis of thalamic size in schizoprenia, 28
Koo J. See Seo J-H
Koss M. See Krakow B
Kosten T. See Boutros NN
Kozel FA. See McConnell KA
Krakow B, Melendrez D, Pedersen B, Johnston L, Hollifield M, Germain A, Koss M, Warner TD, Schrader R. Complex insomnia: Insomnia and sleep-disordered breathing in a consecutive series of crime victims with nightmares and PTSD, 948
Krause S. See Elman I
Krishnan KRR. See MacFall JR
Kroft J. See Barr CL
Krystal JH. See Boutros NN
Kukes TJ. See Kaufman MJ
Kukull WA. The association between smoking and Alzheimer's disease: effects of study design and bias, 194
Kupfer DJ. See Drevets WC
Kupfer DJ. See Soares JC
Kurachi M. See Sumiyoshi T

Lahti AC, Warfel D, Michaelidis T, Weiler MA, Frey K, Tamminga CA. Long-term outcome of patients who receive ketamine during research, 869
Laruelle M. See Kegeles LS
Lattuada E. See Souery D
Lauriello J. See Roberts LW
Lavie R. See Oren DA
Lawrie SM, Whalley HC, Abukmeil SS, Kestelman JN, Donnelly L, Miller P, Best JJK, Owens DGC, Johnstone EC. Brain structure, genetic liability, and psychotic symptoms in subjects at high risk for developing schizophrenia, 811
Lee J-H. See Seo J-H
Lennkh C. See Tauscher J
Lerer B. See Souery D
Levin ED. See Rezvani AH
Levin JM. See Kaufman MJ
Levine J. See Pettegrew JW
Levitt J. See McCarley RW
Lewis L. Unmet needs in diagnosis and treatment of mood disorders in children and adolescents, 960-ed
Li J. See Avenevoli S
Lidow MS, Song Z-M, Castner SA, Allen PB, Greengard P, Goldman-Rakic PS. Antipsychotic treatment induces alterations in dendrite- and spine-associated proteins in dopamine-rich areas of the primate cerebral cortex, 1
Lieberman J, Chakos M, Wu H, Alvir J, Hoffman E, Robinson D, Bilder R. Longitudinal study of brain morphology in first episode schizophrenia, 487
Lieverse R. See Assies J
Light KC. See Girdler SS
Lilli R. See Souery D
Lilly Resistant Schizophrenia Study Group. See Tollefson GD
Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms?, 47
Linszen DH. See Assies J
Lipska BK. See Al-Amin HA
Lisanby SH. See Boutros NN
Lisanby SH, Gutman D, Luber B, Schroeder C, Sackeim HA. Sham TMS: intracerebral measurement of the induced electrical field and the induction of motor-evoked potentials, 460
Liu X, Gershenfeld HK. Genetic differences in the tail-suspension test and its relationship to imipramine response among 11 inbred strains of mice, 575
Lohr JB. See Lindamer LA
Lombardi U. See Zubieta J-K
Lommen U. See Rockstroh B
Loo C, Sachdev P, Elsayed H, McDarmont B, Mitchell P, Wilkinson M, Parker G, Gandevia S. Effects of a 2- to 4-week course of repetitive transcranial magnetic stimulation (rTMS) on neuropsychologic functioning, electroencephalogram, and auditory threshold in depressed patients, 615
Lorberbaum JP. See McConnell KA
Lowers L. See Hill SY
Lubart R. See Oren DA
Luber B. See Lisanby SH
Ludwig J. See Maelicke A
Lukas SE. See Kaufman MJ
Luu-Hsia C. See Schröder J

Maas LC. See Kaufman MJ
MacFall JR, Payne ME, Provenzale JE, Krishnan KRR. Medial orbital frontal lesions in late-onset depressiom, 803
Maelicke A, Samochocki M, Jostock R, Fehrenbacher A, Ludwig J, Albuquerque EX, Zerlin M. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease, 279
Maes RAA. See Bouwknecht JA
Maes RAA. See Pattij, T
Maier SF. Exposure to the stressor environment prevents the temporal dissipation of behavioral depression/learned helplessness, 763
Malaspina D. See Brown AS
Malison R. See Boutros NN
Mallinger AG. See Soares JC
Malone M. See Barr CL
Marin D. See Schröder J
Marsh L. See Ford JM
Martin A. See Kaufman J
Martin-Ruiz C. See Court J

Martinez J. See Coryell W
Massat I. See Souery D
Mathalon DH. See Ford JM
Mathis CA. See Drevets WC
Matsui M. See Sumiyoshi T
Matsumoto H, Simmons A, Williams S, Pipe R, Murray R, Frangou S. Structural magnetic imaging of the hippocampus in early onset schizophrenia, 824
Matt GE. See Siegle GJ
Mattay VS. See Bertolino A
Mayes TL. See Emslie GJ
Mazure CM. See Hoffman RE
McCarley RW. See Gurrera RJ
McCarley RW, Wible CG, Frumin M, Hirayasu Y, Levitt J, Shenton ME. Why vote-count reviews don't count, 162-corr (response)
McCleery JM, Goodwin GM. High and low neuroticism predict different cortisol responses to the combined dexamethasone-CRH test, 410
McClure RJ. See Pettegrew JW
McConaha C, See Kaye WH
McConnell KA, Nahas Z, Shastri A, Lorberbaum JP, Kozel FA, Bohning DE, George MS. The transcranial magnetic stimulation motor threshold depends on the distance from coil to underlying cortex: a replication in healthy adults comparing two methods of assessing the distance to cortex, 454
McDarmont B. See Loo C
McGlashan TM. See Hoffman RE
Melendrez D. See Krakow B
Meltzer HY. See Sumiyoshi T
Mendelson JH. See Kaufman MJ
Mendlewicz J. See Souery D
Menon NK. See Zeng H
Merikangas KR. See Avenevoli S
Merikangas KR. See Kessler RC
Meyer JH. See Fu CHY
Michaelidis T. See Lahti AC
Mick E. See Spencer TJ
Milinova V. See Souery D
Miller AH. See Pariante CM
Miller DD, Andreasen NC, O'Leary DS, Watkins GL, Boles Ponto LL, Hichwa RD. Comparison of the effects of risperidone and haloperidol on regional cerebral blood flow in schizophrenia, 704
Miller P. See Lawrie SM
Minoshima S. See Zubieta J-K
Mitchell P. See Loo C
Miyazaki S. See Honda M
Mohr B. See Rockstroh B
Morrow AL See Girdler SS
Muir W. See Souery D
Müller R-A, Pierce K, Ambrose JB, Allen G, Courchesne E. Atypical patterns of cerebral motor activation in autism: a functional magnetic resonance study, 665
Murphy AM. See Kates WR
Murphy DL. See Enoch M-A
Murray R. See Matsumoto H

Naber D. See Kiefer F
Nagata T. See Kaye WH
Nahas Z. See McConnell KA
Näsman B. See Rasmuson S
Nemeroff CB. See Heim C
Nesse RM. See Abelson JL
Nestor PG. See Gurrera RJ
Neufeld A. See Glied S
Neumeister A. See Tauscher J
Neve RL. See Chen AC-H
Newhouse PA, Potter A, Kelton M, Corwin J. Nicotinic treatment of Alzheimer's disease, 268
Ni LiS. See Zubieta J-K
Nilsson ME. See Casper RC
Nisenbaum LK. See Perry KW
Nohara S. See Sumiyoshi T
Nopoulos PC, Ceilley JW, Gailis EA, Andreasen NC. An MRI study of midbrain morphology in patients with schizophrenia: relationship to psychosis, neuroleptics, and cerebellar neural circuitry, 13
Nordberg A. Nicotinic receptor abnormalities of Alzheimer's disease: therapeutic implications, 200
Nöthen MM. See Barr CL
Nöthen MM. See Souery D

O'Brien D. See Rilling JK
O'Brien J, Thomas A, Ballard C, Brown A, Ferrier N, Jaros E, Perry R. Cognitive impairment in depression is not associated with neuropathologic evidence of increased vascular or Alzheimer-type pathology, 130
O'Donnell BF. See Gurrera RJ
Ohl LE. See Zubieta J-K
Okubo Y. See Ichimiya T
O'Leary BS. See Miller DD
Olivier, B. See Bouwknecht JA
Olivier, B. See Pattij, T
Olsson T. See Rasmuson S
Oosting RS. See Pattij, T
Oren DA, Charney DS, Lavie R, Sinyakov M, Lubart R. Stimulation of reactive oxygen species production by an antidepressant visible light source, 464
Oruc L. See Souery D
Owens DGC. See Lawrie SM

Panchalingam K. See Pettegrew JW
Papadimitriou G. See Souery D
Pariante CM, Miller AH. Glucocorticoid receptors in major depression: relevance to pathophysiology and treatment, 391
Park CH. See Seo J-H
Parker G. See Loo C
Pattij, T, Hijzen TH, Groenink L, Oosting RS, van der Gugten J, Maes RAA, Hen R, Olivier B. Stress-induced hyperthermia in the 5-HT_{1A} receptor knockout mouse is normal, 569
Paulus MP, Rapaport MH, Braff DL. Trait contributions of complex dysregulated behavioral organization in schizophrenic patients, 71
Payne ME. See MacFall JR
Pearlson GD. See Kates WR
Pedersen B. See Krakow B
Pedersen CA. See Girdler SS
Peng L-J. See Zeng H
Perry E. See Court J
Perry KW, Nisenbaum LK, George CA, Shannon HE, Felder CC, Bymaster FP. The muscarinic agonist xanomeline increases monoamine release and immediate early gene expression in the rat prefrontal cortex, 716
Perry R. See O'Brien J
Pettegrew JW, Panchalingam K, Levine J, McClure RJ, Gershon S, Yao JK. Chronic *myo*-inositol increases rat brain phosphatidylethanolamine plasmalogen, 444
Pfeffer CR. Diagnosis of childhood and adolescent suicidal behavior: unmet needs for suicide prevention, 1055
Pfefferbaum A. See Ford JM
Picciotto MT. See George TP
Pierce K. See Müller R-A
Pierce K, Courchesne E. Evidence for a cerebellar role in reduced

exploration and stereotyped behavior in autism, 655
Piggott M. See Court J
Pine D. See Coryell W
Pipe R. See Matsumoto H
Pirker W. See Tauscher J
Pitts T. See Hill SY
Plotnicov KH. See Kaye WH
Polich J. See Hada M
Porges SW. See Sahar T
Porjesz B. See Hada M
Post RM. See Ketter TA
Potter A. See Newhouse PA
Praschak-Rieder N. See Tauscher J
Price JC. See Drevets WC
Price JL. See Drevets WC
Propping P. See Souery D
Provenzale JE. See MacFall JR

Quinlan DM. See Hoffman RE

Rah J-C. See Seo J-H
Rajkowska G, Halaris A, Selemon LD. Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder, 741
Rakow R. See Bertolino A
Rapaport MH. See Paulus MP
Rasmuson S, Andrew R, Näsman B, Seckl JR, Walker BR, Olsson T. Increased glucocorticoid production and altered cortisol metabolism in women with mild to moderate Alzheimer's disease, 547
Rattray M. Is there nicotinic modulation of nerve growth factor? Implications for cholinergic therapies in Alzheimer's disease, 185
Reed LJ. See Fu CHY
Reiss AL. See Eliez S
Renshaw PF. See Kaufman MJ
Rezvani AH, Levin ED. Cognitive effects of nicotine, 260
Rilling JK, Winslow JT, O'Brien D, Gutman DA, Hoffman JM, Kilts CD. Neural correlates of maternal separation in rhesus monkeys, 146
Roberts LW, Lauriello J, Geppert C, Keith SJ. Placebos and paradoxes in psychiatric research: an ethics perspective, 887
Roberts W. See Barr CL
Robinson D. See Lieberman J
Rockstroh B, Kissler J, Mohr B, Eulitz C, Lommen U, Wienbruch C, Cohen R, Elbert T. Altered hemispheric asymmetry of auditory magnetic fields to tones and syllables in schizophrenia, 694
Rossell SL. See Shapleske J
Roth RH. See George TP
Roth WT. See Wilhelm FH
Rubio A, Vestner AL, Stewart JM, Forbes NT, Conwell Y, Cox C. Suicide and Alzheimer's pathology in the elderly: a case–control study, 137
Ruskin DN, Bergstrom DA, Shenker A, Freeman LE, Baek D, Walters JR. Drugs used in the treatment of attention-deficit/hyperactivity disorder affect postsynaptic firing rate and oscillation without preferential dopamine autoreceptor action, 340
Rutberg J. See Kates WR
Rutter M. See Silberg JL
Ryan ND. See Goetz RR
Ryan ND. See Thomas KM
Ryan ND. Diagnosing pediatric depression, 1050

Sachdev P. See Loo C
Sackeim HA. See Lisanby SH
Safer DJ. See Zito JM
Sahar T, Shalev AY, Porges SW. Vagal modulation of responses to mental challenge in posttraumatic stress disorder, 637
Salomon AR. See Zeng H
Samochocki M. See Maelicke
Schachar R. See Barr CL
Schmitt JE. See Eliez S
Schoenfeld DA. See Elman I
Schrader R. See Krakow B
Schreiber S. See Dolberg OT
Schröder J, Buchsbaum MS, Shihabuddin L, Tang C, Wei T-C, Spiegel-Cohen J, Hazlett EA, Abel L, Luu-Hsia C, Ciaravolo TM, Marin D, Davis KL. Patterns of cortical activity and memory performance in Alzheimer's disease, 426
Schroeder C. See Lisanby SH
Schulze T. See Souery D
Seckl JR. See Rasmuson S
Seeman, P. See Kapur S
Selemon LD. See Rajkowska G
Seo J-H, Kim S-H, Kim H-S, Park CH, Jeong S-J, Lee J-H, Choi SH, Chang K-A, Rah J-C, Koo J, Kim E-M, Suh Y-H. Effects of nicotine on APP secretion and Aβ- or CT_{105}-induced toxicity, 240
Sernyak MJ. See Woods SW
Serretto A. See Souery D
Shalev AY. See Sahar T
Shannon HE. See Perry KW
Shao H. See Zeng H
Shapira B. See Souery D
Shapleske J, Rossell SL, Simmons A, David AS, Woodruff PWR. Are auditory hallucinations the consequence of abnormal cerebral lateralization? A morphometric MRI study of the sylvian fissure and planum temporale, 685
Shastri A. See McConnell KA
Shen S. See Hill SY
Shenker A. See Ruskin DN
Shenton ME. See McCarley RW
Shihabuddin L. See Schröder J
Shimohama S, Kihara T. Nicotinic receptor–mediated protection against β-amyloid neurotoxicity, 233
Shin K-H. See Chen AC-H
Shin YC. See Kim SW
Shirayama Y. See Chen AC-H
Shoham S, Javitt DC, Heresco-Levy U. Chronic high-dose glycine nutrition: effects on rat brain cell morphology, 876
Siegle GJ, Granholm E, Ingram RE, Matt GE. Pupillary and reaction time measures of sustained processing of negative information in depression, 624
Silberg JL, Rutter M, Eaves L. Genetic and environmental influences on the temporal association between earlier anxiety and later depression in girls, 1040
Simmons A. See Matsumoto H
Simmons A. See Shapleske J
Sinyakov M. See Oren DA
Smeraldi E. See Souery D
Soares JC, Boada F, Spencer S, Mallinger AG, Dippold CS, Wells KF, Frank E, Keshavan MS, Gershon S, Kupfer DJ. Brain lithium concentrations in bipolar disorder patients: preliminary ^{7}Li magnetic resonance studies at 3 T, 437
Sokol MS. See Kaye WH
Song Z-M. See Lidow MS
Souery D, Van Gestel S, Massat I, Blairy S, Adolfsson R, Blackwood D, Del-Favero J, Dikeos D, Jakovljevic M,

Kaneva R, Lattuada E, Lerer B, Lilli R, Milinova V, Muir W, Nöthen MM, Oruc L, Papadimitriou G, Propping P, Schulze T, Serretti A, Shapira B, Smeraldi E, Stefanis C, Thomson M, Van Broeckhoven C, Mendlewicz J. Tryptophan hydroxylase polymorphism and suicidality in unipolar and bipolar affective disorders: a multicenter association study, 405
Speer AM. See Ketter TA
Spencer S. See Soares JC
Spencer TJ, Biederman J, Wozniak J, Faraone SV, Wilens TE, Mick E. Parsing pediatric bipolar disorder from its associated comorbidity with the disruptive behavior disorders, 1062
Spiegel-Cohen J. See Schröder J
Spurden D. See Court J
Stefanis C. See Souery D
Stewart JM. See Rubio A
Stolar M. See Avenevoli S
Stolar M. See Woods SW
Straneva PA. See Girdler SS
Strauss WL, Dager SR. Magnetization transfer of fluoxetine in the human brain using fluorine magnetic resonance spectroscopy, 798
Stuart BK. See Kayser J
Sudo Y. See Ichimiya T
Suh Y-H. See Seo J-H
Suhara T. See Ichimiya T
Sumiyoshi C. See Sumiyoshi T
Sumiyoshi S. See Sumiyoshi T
Sumiyoshi T, Matsui M, Yamashita I, Nohara S, Kurachi M, Uehara T, Sumiyoshi S, Sumiyoshi C, Meltzer HY. The effect of tandospirone, a serotonin$_{1A}$ agonist, on memory function in schizophrenia, 861
Sunohara G. See Barr CL
Susser ES. See Brown AS
Sved AF. See Jedema HP

Tamminga CA. See Lahti AC
Tang C. See Schröder J
Tannock R. See Barr CL
Tauscher J, Pirker W, Willeit M, de Zwaan M, Bailer U, Neumeister A, Asenbaum S, Lennkh C, Praschak-Rieder N, Brücke T, Kasper S. [^{123}I] β-CIT and single photon emission computed tomography reveal reduced brain serotonin transporter availability in bulimia nervosa, 326
Taylor SF. See Zubieta J-K
Tenke CE. See Kayser J
Thomas A. See O'Brien J
Thomas KM, Drevets WC, Whalen PJ, Eccard CH, Dahl RE, Ryan ND, Casey BJ. Amygdala response to facial expressions in children and adults, 309
Thomson M. See Souery D
Tokunaga K. See Honda M
Tokuno H. See Boutros NN
Tollefson GD. See Casper RC
Tollefson GD, Birkett MA, Kiesler GM, Wood AJ, and The Lilly Resistant Schizophrenia Study Group. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine, 52
Tooney PA, Crawter VC, Chahl LA. Increased tachykinin NK$_1$ receptor immunoreactivity in the prefrontal cortex in schizophrenia, 523
Torello MW. See Boutros NN
Torstenson OL. The treatment of mood disorders in children and adolescents by general pediatricians, 970
Trabert, W. See Wilhelm FH

Uchida S. See Honda M
Uehara T. See Sumiyoshi T
Uhl G. See Barr CL

Van Broeckhoven V. See Souery D
Vandenbergh DJ. See Barr CL
van der Gugten J. See Bouwknecht JA
van der Gugten J. See Pattij, T
Van Gestel S. See Souery D
Verrico CD. See George TP
Vestner AL. See Rubio A
Villafuerte RA. See Kaufman MJ
Volkow ND, Ding Y-S, Fowler JS, Gatley SJ. Imaging brain cholinergic activity with positron emission tomography: its role in the evaluation of cholinergic treatments in Alzheimer's dementia, 211
Vreken P. See Assies J

Walker BR. See Rasmuson S
Walters JR. See Ruskin DN
Wanders RJA. See Assies J
Warfel D. See Lahti AC
Warner TD. See Krakow B
Watkins GL. See Miller DD
Weg JG. See Abelson JL
Wei T-C. See Schröder J
Weickert CS. See Al-Amin HA
Weidenhammer KM. See Bertolino A
Weiler MA. See Lahti AC
Weinberger DR. See Al-Amin HA
Weinberger DR. See Bertolino A
Weise J. See Kaye WH
Weiss JM. See Grant MM
Weissman MM. See Goetz RR
Wellis VG. See Eliez S
Wells KB, Kataoka SH, Asarnow JR. Affective disorders in children and adolescents: addressing unmet need in primary care settings, 1111
Wells KF. See Soares JC
Weltzin TE. See Kaye WH
Whalen PJ. See Thomas KM
Whalley HC. See Lawrie SM
White CD. See Eliez S
Wible CG. See McCarley RW
Wiedemann K. See Kiefer F
Wienbruch C. See Rockstroh B
Wigg K. See Barr CL
Wilens TE. See Spencer TJ
Wilhelm FH, Trabert W, Roth WT. Characteristics of sighing in panic disorder, 606
Wilhelm FH, Trabert W, Roth WT. Physiologic instability in panic disorder and generalized anxiety disorder, 596
Wilkinson M. See Loo C
Willeit M. See Tauscher J
Williams S. See Matsumoto H
Willis MW. See Ketter TA
Winslow JT. See Rilling JK
Wolf K. See Kiefer F
Wolk SI. See Goetz RR
Wood AJ. See Tollefson GD
Woodruff PWR. See Shapleske J
Woods SW, Stolar M, Sernyak MJ, Charney DS. Consistency of atypical antipsychotic superiority to placebo in recent clinical trials, 64
Wozniak J. See Spencer TJ
Wu H. See Lieberman J

Xu C. See Barr CL

Yamashita I. See Sumiyoshi T
Yang J. See Zeng H
Yao JK. See Pettegrew JW

Zagorski MG. See Zeng H

Zai G. See Barr CL
Zamani MR, Allen YS. Nicotine and its interaction with β-amyloid protein: a short review, 221
Zeng H, Zhang Y, Peng L-J, Shao H, Menon NK, Yang J, Salomon AR, Freidland RP, Zagorski MG. Nicotine and amyloid formation, 248
Zerlin M. See Maelicke A
Zhang Y. See Zeng H
Zito JM, Safer DJ. Services and prevention: pharmacoepidemiology of antidepressant use, 1121
Zubieta J-K, Lombardi U, Minoshima S, Guthrie S, Ni LiS, Ohl LE, Koeppe RA, Domino EF. Regional cerebral blood flow effects of nicotine in overnight abstinent smokers, 906
Zubieta J-K, Taylor SF, Huguelet P, Koeppe RA, Kilbourn MR, Frey KA. Vesicular monoamine transporter concentrations in bipolar disorder type I, schizophrenia, and healthy subjects, 110

Subject Index to Volume 49

ABT-418
  effects in Alzheimer disease, 268, 279
N-Acetylaspartate
  brain levels affected by antipsychotic agents in schizophrenia, 39
Acetylcholine
  and nerve growth factor production, 185
Acetylcholinesterase
  inhibitors of. *See* Cholinesterase inhibitors
Adolescents
  amygdala volume in offspring at risk for alcoholism, 894
  hippocampal volume reduction in early onset schizophrenia, 824
  mood disorders in. *See* Mood disorders in children and adolescents
  polysomnographic signs in depression, 930
Adrenal steroids
  glucocorticoid receptors in major depression, 391
  production in women with Alzheimer disease, 546
α_2-Adrenoceptors
  and noradrenergic dysfunction in depression, 317
Affective disorders in children. *See* Mood disorders in children and adolescents
Aggression
  and serotonin receptors affecting impulse control, 557
Aging
  and cognitive impairment in depression, 130
  and estrogen replacement therapy affecting negative symptoms in schizophrenia, 47
  and medial orbital frontal lesions in depression, 803
  suicide and Alzheimer's pathology in, 137
Airway resistance syndrome
  and complex insomnia in posttraumatic stress syndrome, 948
Alcoholism
  and amygdala volume in offspring at risk, 894
  and leptin as modulator of alcohol craving, 782
  risk in males with auditory P3a deficits, 726
Allopregnanlone
  plasma levels in premenstrual dysphoric disorder, 788
Alzheimer disease
  amyloid precursor protein release affected by nicotine, 240
  β-amyloid protein production in, 221
  association with smoking, 194
  cholinergic therapy evaluation with PET studies, 211
  and cognitive effects of nicotine, 258
  cortical activity patterns in, 426
  and glucocorticoid production in women, 546
  nerve growth factor production in, 185
  neuroprotection with nicotinic receptor stimulation, 233
  and nicotine binding to β-amyloid, 248
  nicotinic mechanisms in, 165–ed
  nicotinic receptor abnormalities in, 175
    therapeutic implications of, 200
  nicotinic treatment of, 268
  and suicide in elderly persons, 137
  therapy with allosteric modulation of nicotinic receptors, 279, 289
cAMP response element binding protein (CREB)
  over-expression in hippocampus producing antidepressant effect, 753
Amphetamines
  affecting dopamine autoreceptors in attention-deficit/hyperactivity disorder, 340
  and ventral striatal dopamine release related to euphoria, 81
Amygdala
  response to facial expressions, 309
  volume in offspring at risk for alcoholism, 894
Amyloid
  plaque detection with PET studies, 211
  precursor protein
    APP 670/671 mutation in Alzheimer disease, 200
    secretion affected by nicotine, 240
β-Amyloid protein
  interaction with nicotine, 221
  neurotoxicity mediated by nicotinic receptors, 233, 240
  nicotine binding to Aá peptide, 248
Animal studies
  brain cell morphology affected by glycine, 876
  cognitive effects of nicotine, 258
  and drug development in schizophrenia, 374
  expression of cAMP response element binding protein in hippocampus, 753
  genetic differences in tail-suspension test in mice, 575
  haloperidol affecting cellular morphology in brain, 1
  myo-inositol affecting rat brain plasmalogen, 444
  locus coeruleus activation by corticotropin-releasing hormone in cold stress, 351
  neonatal hippocampal lesions affecting responses to MK-801, 528
  neural correlates of maternal separation, 146
  nicotine affecting conditioned fear stress in rats, 300
  serotonin 1B receptor knockout mice, 557
  stress-induced hyperthermia in serotonin 1A receptor knockout mice, 569
  time course of behavioral depression, 763
  xanomeline affecting dopamine levels and early gene expression in prefrontal cortex, 704
Anorexia nervosa
  fluoxetine in, 644

Abbreviations:
ed: editorial
corr: correspondence

© 2001 Society of Biological Psychiatry

0006-3223/01/$20.00
PII S0006-3223(01)01193-3

Antidepressants
and expression of cAMP response element binding protein in hippocampus, 753
and glucocorticoid receptor function in major depression, 391
and locus coeruleus electrophysiology, 117
in mood disorders of children and adolescents, 1082
prevalence of use, 1121
responses to fluoxetine affected by hemispheric asymmetry, 416
Antipsychotic agents
affecting regional cerebral blood flow, 704
and brain *N*-acetylaspartate measures in schizophrenia, 39
and cellular morphology in cerebral cortex, 1
clinical trials in schizophrenia, 374
and midbrain morphology in schizophrenia, 13
in placebo-controlled clinical trials, 64
xanomeline affecting dopamine levels and early gene expression in prefrontal cortex, 704
Anxiety
and comorbid depression in families of children with mood disorders, 1071
developmental changes in, 971
early symptoms affecting later depression in girls, 1040
and locus coeruleus activation by corticotropin-releasing hormone in cold stress, 351
and neural correlates of maternal separation in monkeys, 146
physiologic instability in, 596
role of childhood trauma in, 1023
sighing in, 606
Attention
nicotine affecting, 258
Attention-deficit/hyperactivity disorder
comorbidity with pediatric bipolar disorder, 1062
drugs affecting dopamine autoreceptors in, 340
effects of nicotine in, 258
linkage with *DAT1* gene, 333
Auditory event-related potentials
N1 and P300 abnormalities in schizophrenia and epilepsy, 848
P3 amplitude in major personality traits, 922
P3a deficits and alcoholism risk in males, 726
tonal and phonetic tasks in schizophrenia, 832
Auditory processing
and hemispheric asymmetry in schizophrenia, 694
threshold after 4-week course of transcranial magnetic stimulation, 615
Autism
and cerebellar role in exploration behavior, 655
motor activation patterns in, 665

Behavior
dysregulation in schizophrenia, 71
Behavioral science
and mood disorders in children and adolescents, 962
Behavioral tests
and expression of cAMP response element binding protein in hippocampus, 753
Bennett Research Award
prenatal rubella and schizophrenia, 473
Bipolar disorder
brain lithium levels in, 437
cerebral metabolism in, 97
in children
comorbidity with disruptive behavior disorders, 1062
and financial aspects of mental health services, 1128
psychopharmacological treatment, 1082
mania induced by transcranial magnetic stimulation, 469
prefrontal cortex cellular architecture in, 741
tryptophan hydroxylase polymorphism in, 405
vesicular monoamine transporter binding sites in, 110
Blood flow, cerebral
clonidine affecting, 317
and cortical activity patterns in Alzheimer disease, 426
haloperidol affecting, 704
nicotine affecting, 906
risperidone affecting, 704
Body temperature
in serotonin 1A receptor knockout mice, 569
in serotonin 1B receptor knockout mice, 557
Brain
N-acetylaspartate levels affected by antipsychotic agents, 39
cellular morphology affected by haloperidol, 1
cerebral metabolism in bipolar disorder, 97
cortical excitability affected by cocaine, 369
glycine affecting morphology, 876
lithium levels in bipolar disorder, 437
midbrain morphology in schizophrenia, 13
morphology in first episode schizophrenia, 487
neuropathology
and cognitive impairment in depression, 130
and suicide risk in Alzheimer disease, 137
nicotinic receptor abnormalities in Alzheimer disease, 175
therapeutic implications of, 200
reduced cerebellar vermis volume in schizophrenia, 20
serotonin transporters in bulimia nervosa, 326
structural abnormalities in high-risk subjects, 811
thalamus size in schizophrenia, 28
in velocardiofacial syndrome
posterior fossa development, 540
white matter reductions, 677
ventral striatal dopamine release related to euphoria, 81
vesicular monoamine transporter binding sites in bipolar disorder and schizophrenia, 110
Bulimia nervosa
SPECT studies in, 326

Calcium channels
density in brain affected by glycine, 876
Carbon dioxide
respiratory sensitivity to, in familial panic disorder, 582
Central nervous system
nicotinic receptors in, 166
Cerebellum
abnormal morphology in schizophrenia, 13

reduced volume of vermis in schizophrenia, 20
role in behaviors in autism, 655
Cerebral cortex
cellular morphology affected by haloperidol, 1
nicotinic receptor abnormalities in Alzheimer disease, 175
therapeutic implications of, 200
Cerebrovascular disorders
and vasoconstrictive effects of cocaine in women, 774
Children
amydala responses to facial expressions, 309
cerebellar role in behaviors in autism, 655
linkage of *DAT1* gene and attention-deficit/hyperactivity disorder, 333
mood disorders in. *See* Mood disorders in children and adolescents
motor activation patterns in autism, 665
Cholinergic therapy
and activation of nicotinic receptors, 200
evaluation with PET studies in Alzheimer disease, 211
and nerve growth factor production, 185
Cholinesterase inhibitors
affecting nicotinic receptors in Alzheimer disease, 200, 279
evaluation with PET studies in Alzheimer disease, 211
galantamine affecting nicotinic receptors, 279, 289
Clinical trials
antipsychotic agents in schizophrenia, 374
for children with mood disorders
ethical issues in, 1015
NIMH perspective, 960
consistency of antipsychotics compared to placebos, 64
fluoxetine in anorexia nervosa, 644
naltrexone in treatment of pathological gambling, 914
olanzapine compared to clozapine in schizophrenia, 52
placebos and paradoxes in, 887
therapy affecting whole blood serotonin changes in obsessive-compulsive disorder, 360
Clomipramine
and whole blood serotonin changes in obsessive-compulsive disorder, 360
Clonidine
and noradrenergic dysfunction in prefrontal cortex, 317
Clozapine
compared to olanzapine in schizophrenia, 52
Cocaine
clinical outcomes after infusions in research, 553
effects on cortical excitability, 369
vasoconstrictive effects in menstrual cycle phases, 774
Codeine
in allosteric sensitization of nicotinic receptors, 279
Cognition
and dysregulated behavior in schizophrenia, 71
impairment in depression, 130
neurocognitive deficits in schizophrenia, 374
nicotine affecting, 258
tandospirone affecting, in schizophrenia, 861
Cognitive behavior therapy
in childhood and adolescent depression, 1091
Cold stress
and locus coeruleus activation by corticotropin-releasing hormone, 351
Comorbidity
conduct disorder with pediatric bipolar disorder, 1062
depression and anxiety in families of children with mood disorders, 1071
in mood disorders of children and adolescents, 1002
Conditioned fear stress
responses in rats affected by nicotine, 300
Conduct disorder
comorbidity with pediatric bipolar disorder, 1062
Corticosterone levels
in serotonin 1A receptor knockout mice, 569
Corticotropin-releasing hormone
and locus coeruleus activation in cold stress, 351
secretion in depressed children and adults, 980
Cortisol
metabolism in women with Alzheimer disease, 546
plasma levels related to maternal separation in monkeys, 146
responses to dexamethasone–CRH test in depression and in posttraumatic stress disorder, 410
Crime victims
complex insomnia in, 948

Dendritic proteins
haloperidol affecting, 1
Depression
in bipolar disorder. *See* Bipolar disorder
in children and adolescents. *See* Mood disorders in children and adolescents
cognitive impairment in, 130
and cortisol response to dexamethasone–CRH test, 410
and early anxiety symptoms in girls, 1040
and emotional states in developmental stages, 973
medial orbital frontal lesions in, 803
neurobiological correlations in children, adolescents, and adults, 980
and noradrenergic dysfunction in prefrontal cortex, 317
and premorbid polysomnographic signs in adolescents, 930
and reactive oxygen species produced from light, 464
response to fluoxetine affected by hemispheric asymmetry, 416
role of childhood trauma in, 1023
and time course of learned helplessness, 763
tryptophan hydroxylase polymorphism in, 405
Depressive disorder, major
effects of 4-week course of transcranial magnetic stimulation, 615
glucocorticoid receptors in, 391
and *myo*-inositol affecting rat brain plasmalogen, 444
and placebo responses in women and men, 158
sustained processing of emotional information in, 624
Desipramine
affecting locus coeruleus electrophysiology, 117
Developmental stages
and amydala responses to facial expressions, 309

early childhood trauma affecting neurobiology in, 1023
emotional states in, 973
and mood disorders in children and adolescents, 962
and neurodevelopmental hypothesis of schizophrenia, 473
Dexamethasone suppression test
studies in depressed children and adolescents, 980
Dexamethasone–CRH test
and glucocorticoid receptor resistance in depression, 391
responses in neuroticism, 410
Diazepam
effects in serotonin 1A receptor knockout mice, 569
Dichotic listening
and prediction of response to fluoxetine, 416
Disinhibition, cortical
and alcoholism risk with auditory P3a deficits, 726
Dizocilpine-induced hyperactivity
after neonatal lesions of hippocampus, 528
Donepezil
in allosteric sensitization of nicotinic receptors, 279
Dopamine
autoreceptors affected by drugs in attention-deficit/hyperactivity disorder, 340
cortical levels in conditioned fear stress in rats, 300
ketamine affinity for D2 receptors, 954–corr
release in prefrontal cortex affected by xanomeline, 704
transporter locus gene linked to attention-deficit/hyperactivity disorder, 333
ventral striatal release related to euphoria, 81
and vesicular monoamine transporter binding sites in bipolar disorder and schizophrenia, 110
Dysregulation
and behavior in schizophrenia, 71

Eating disorders
fluoxetine in anorexia nervosa, 644
SPECT studies in bulimia nervosa, 326
Elderly persons. *See* Aging
Electroconvulsive therapy
and locus coeruleus electrophysiology, 117
Electroencephalography
and prediction of response to fluoxetine, 416
Emotion
and amygdala response to facial expressions, 309
developmental changes in, 973
Epidemiology
mood disorders in children and adolescents, 1002
Epilepsy
event-related potentials compared to schizophrenia patients, 848
Equivalence study
and consistency of antipsychotics compared to placebos, 64
Errata
Baxter article (1985), 80
Stoll article (2000;48:505-517), 80
Vawter article (2000;48[6]), 80
Erythrocytes
fatty acid levels in schizophrenia, 510
Estrogen replacement therapy
and negative symptoms in women with schizophrenia, 47
Ethical issues
long-term outcome of schizophrenic volunteers receiving ketamine, 869
placebos and paradoxes in research, 887
in research and treatment of children with mood disorders, 1015
Euphoria
related to ventral striatal dopamine release, 81
Event-related potentials
auditory
in major personality traits, 922
N1 and P300 abnormalities in schizophrenia and epilepsy, 848
P3a deficits and alcoholism risk in nales, 726
tonal and phonetic tasks in schizophrenia, 832
visual
relation to amygdala volume in offspring at risk for alcoholism, 894
Exploration behavior
in autism, cerebellar role in, 655

Facial expressions
amygdala response to, 309
Families
amygdala volume in offspring at risk for alcoholism, 894
comorbid depression and anxiety in adults and children, 1069
disorders affecting depressed children, adolescents, and adults, 980
neural correlates of maternal separation in monkeys, 146
panic disorder in, and respiratory sensitivity to CO_2, 582
prevention programs for children with depressed parents, 1101
Family therapy
in childhood and adolescent depression, 1091
Fatty acids
erythrocyte, in recent-onset schizophrenia, 510
Fibroblasts
reactive oxygen species produced from light therapy, 464
First episode schizophrenia
brain morphology in, 487
Five-Factor Inventory
and auditory P3 amplitude in personality traits, 922
Flesinoxan
effects in serotonin 1A receptor knockout mice, 569
Fluoxetine
in anorexia nervosa, 644
hemispheric asymmetries affecting responses to, 416
magnetization transfer spectroscopy in brain, 798
in mood disorders of children and adolescents, 1082
Follow-up studies
premorbid polysomnographic signs in depressed adolescents, 930
Forced swim test
and expression of cAMP response element binding protein in hippocampus, 753

c-fos
expression in prefrontal cortex affected by xanomeline, 704
Frontal cortex
medial orbital lesions in depression, 803
Frontal lobes
auditory P3a deficits and high risk for alcoholism, 726
role in behaviors in autism, 655

Galantamine affecting nicotinic receptors, 279
in Alzheimer disease, 289
Gambling, pathological
naltrexone therapy in, 914
Gender
alcoholism risk in males with auditory P3a deficits, 726
auditory P3a deficits and alcoholism risk in males, 726
early anxiety affecting later depression in girls, 1040
glucocorticoid production in women with Alzheimer disease, 546
and placebo responses in major depression, 158
and response to fluoxetine affected by hemispheric asymmetry, 416
serotonin receptor gene promoter polymorphism in obsessive-compulsive disorder in women, 385
vasoconstrictive effects of cocaine in women, 774
Genetics
and early anxiety affecting later depression in girls, 1040
early gene expression in prefrontal cortex affected by xanomeline, 704
liability to schizophrenia related to brain volumes, 811
linkage of *DAT1* gene and attention-deficit/hyperactivity disorder, 333
and mood disorders in children and adolescents, 962
serotonin receptor gene promoter polymorphism in obsessive-compulsive disorder in women, 385
tail-suspension test in inbred mouse strains, 575
tryptophan hydroxylase polymorphism in affective disorders, 405
Globus pallidus
activity affected by drugs in attention-deficit/hyperactivity disorder, 340
Glucocorticoids
production in women with Alzheimer disease, 546
receptors in major depression, 391
Glucose
cerebral metabolism in bipolar disorder, 97
Glutamate
and nerve growth factor production, 185
neurotoxicity affected by nicotine, 233
Glycine
affecting brain morphology, 876
Growth hormone
secretion in depressed children and adolescents, 980
GTS-21
affecting learning and memory, 268

Hallucinations
auditory, cerebral lateralization in, 685
Haloperidol
affecting regional cerebral blood flow, 704
and cellular morphology in cerebral cortex, 1
Hearing
after 4-week course of transcranial magnetic stimulation, 615
Heart rate
in serotonin 1B receptor knockout mice, 557
and vagal tone in challenge test in posttraumatic stress disorder, 637
Helplessness, learned
and expression of cAMP response element binding protein in hippocampus, 753
time course in rats, 763
Hemispheric asymmetry
and auditory event-related potentials in schizophrenia, 832
and auditory hallucinations, 685
and auditory processing in schizophrenia, 694
and responses to fluoxetine, 416
Hippocampus
expression of cAMP response element binding protein in, 753
glucocorticoid receptors in Alzheimer disease, 546
morphology in first episode schizophrenia, 487
neonatal lesions affecting responses to MK-801, 528
nerve growth factor production affected by nicotine, 185
volume reduction in early onset schizophrenia, 824
HLA antigen
in monozygotic narcoleptic twins, 943
Hormone replacement therapy
and negative symptoms in women with schizophrenia, 47
Hyperthermia
stress-induced, in serotonin 1A receptor knockout mice, 569
Hypothalamic–pituitary–adrenal axis
hyperactivity in major depression, 391
and leptin role in alcohol craving, 782
in neuroticism, 410

Imidazoline
receptors binding to clonidine, 317
Imipramine
affecting locus coeruleus electrophysiology, 117
effects in tail-suspension test in inbred mouse strains, 575
in mood disorders of children and adolescents, 1082
Immobility response
and conditioned fear stress in rats, 300
and expression of cAMP response element binding protein in hippocampus, 753
and tail-suspension test in inbred mouse strains, 575
Immunohistochemistry
neurokinin-1 receptors in schizophrenia, 523
Impulse control
and naltrexone in pathological gambling, 914
serotonin receptors affecting, 557
Information processing
and pupil dilation in depression, 624
myo-Inositol
affecting rat brain plasmalogen, 444
Insomnia
in crime victims with posttraumatic stress disorder, 948

Insurance
and financial aspects of mental health services for children, 1128
Intermittency
and dysregulation of behavior in schizophrenia, 71
Interpersonal psychotherapy
in childhood and adolescent depression, 1091

Ketamine
affinity for NMDA and dopamine D_2 receptors, 954–corr
and long-term outcome of schizophrenic volunteers in research, 869

Lateralization in brain. *See* Hemispheric asymmetry
Leptin
as modulator of alcohol craving, 782
Light therapy
and reactive oxygen species produced in fibroblasts, 464
Lithium
brain levels in bipolar disorder, 437
Locomotor activity
in serotonin 1B receptor knockout mice, 557
Locus coeruleus
activation in cold stress affected by corticotropin-releasing hormone, 351
electrophysiology affected by antidepressants, 117

Magnetic resonance imaging
brain function in depressed children, adolescents, and adults, 980
brain morphology in first episode schizophrenia, 487
brain structure in high-risk subjects, 811
cerebellar vermis volume in schizophrenia, 20
cortical activity patterns in Alzheimer disease, 426
functional
amydala responses to facial expressions, 309
cocaine-induced cerebral vasoconstriction in women, 774
motor activation patterns in autism, 665
hippocampal volume reduction in early onset schizophrenia, 824
medial orbital frontal lesions in depression, 803
midbrain morphology in schizophrenia, 13
posterior fossa in velocardiofacial syndrome, 540
sylvian fissure and planum temporale dimensions in schizophrenia with auditory hallucinations, 685
volumetric analysis of white matter in velocardiofacial syndrome, 677
Magnetic resonance spectroscopy
brain lithium levels in bipolar disorder, 437
and magnetization transfer of fluoxetine in brain, 798
Magnetic stimulation, transcranial
cortical excitability with cocaine use, 369
inducing mania in bipolar depression, 469
motor threshold dependence on distance from coil to cortex, 454
safety of 4-week course of treatment, 615
sham TMS in controlled trials, 460
Magnetization transfer spectroscopy
of fluoxetine in brain, 798
Magnetoencephalography
auditory fields in schizophrenia, 694
Mania. *See also* Bipolar disorder
cortical instability in, 500
Mecamylamine
affecting learning and memory, 268
Memory
and cortical activity patterns in Alzheimer disease, 426
tandospirone affecting, in schizophrenia, 861
Menstrual cycle
allopregnanlone levels in premenstrual dysphoric disorder, 788
vasoconstrictive effects of cocaine in, 774
Mental health services for children and adolescents
in affective disorders, 1111
financial aspects of, 1128
and prevalence of antidepressant treatment, 1121
Mesencephalon
morphology in schizophrenia, 13
Meta-analysis
consistency of antipsychotics compared to placebos, 64
thalamus size in schizophrenia, 28
Metabolism
cerebral, in bipolar disorder, 97
N-Methyl-D-aspartate (NMDA)
ketamine affinity for receptors, 954–corr
receptor agonist (glycine) affecting brain cell morphology, 876
responses to antagonist MK-801 after hippocampal lesions, 528
Methylphenidate
affecting dopamine autoreceptors in attention-deficit/hyperactivity disorder, 340
Metrifonate
in allosteric sensitization of nicotinic receptors, 279
Mianserin
affecting locus coeruleus electrophysiology, 117
Microtubule-associated protein 2 (MAP2)
haloperidol affecting, 1
Midbrain
morphology in schizophrenia, 13
MK-801-induced hyperactivity
after neonatal lesions of hippocampus, 528
Mood disorders in children and adolescents
and age at first treatment of depression or mania, 1002
and child mental health services, 1111
and comorbid depression and anxiety in families, 1071
comorbidity of bipolar disorder and disruptive behavior disorders, 1062
diagnosing pediatric depression, 1050
diagnosing suicidal behavior, 1055
early anxiety affecting later depression in girls, 1040
epidemiology, 1002
and ethical issues in research and therapy, 1015
and financial aspects of mental health services for children, 1128
neurobiological correlates with adult-onset depression, 980
NIMH perspective, 962

and prevalence of antidepressant treatment, 1121
prevention of, 1101
psychopharmacological treatment, 1082
psychotherapies for, 1091
role of early trauma in, 1023
treatment by general pediatricians, 970
unmet needs in, 959–ed, 960–ed
Motor cortex
distance from TMS coil affecting motor threshold, 454
excitability affected by cocaine use, 369
Movements
cerebral motor activations in autism, 665
Muscarinic agonists
xanomeline affecting dopamine levels and early gene expression in prefrontal cortex, 704
Muscarinic receptors
PET studies in Alzheimer disease, 211

Naltrexone
in treatment of pathological gambling, 914
Narcolepsy
in incompletely concordant monozygotic twins, 943
Necker cube stimulus
and neural network in mania, 500
Nerve growth factor
nicotinic modulation of, 185
Neural network
in manic states, 500
Neurobiology, developmental
comparative studies of depressed children, adolescents, and adults, 980
early childhood trauma affecting, 1023
and mood disorders in children and adolescents, 962
Neurocognitive deficits
in schizophrenia, 374
Neurokinin-1 receptors
increase in schizophrenia, 523
Neuroleptics. *See* Antipsychotic agents
Neuropathology
and cognitive impairment in depression, 130
and suicide risk in Alzheimer disease, 137
Neuropsychologic function
after 4-week course of transcranial magnetic stimulation, 615
Neuroticism
dexamethasone-CRH test in, 410
Neurotoxicity
and brain cell morphology affected by glycine, 876
Neurotrophin
receptors bound by nerve growth factor, 185
Nicotine
and amyloid precursor protein secretion, 240
binding to β-amyloid, 248
cognitive effects of, 258
effects on regional cerebral blood flow, 906
interaction with β-amyloid protein, 221
and nerve growth factor production, 185
and responses to conditioned fear stress in rats, 300
Nicotinic receptors
abnormalities in Alzheimer disease, 175
therapeutic implications of, 200
allosteric modulation by galantamine, 279
in Alzheimer disease, 289
PET studies in Alzheimer disease, 211
properties of, 221
and protection against β-amyloid neurotoxicity, 233, 240
roles in central nervous system, 166
stimulation affecting learning and memory, 268
Nightmares
in crime victims with posttraumatic stress disorder, 948
Nocebo effects
in women and men with major depression, 158
Noise, cortical
and neural network in mania, 500
Nuclear magnetic resonance
measures of *myo*-inositol affecting rat brain plasmalogen, 444
spectroscopy of nicotine binding to β-amyloid, 248
Nucleus accumbens
dopamine levels in conditioned fear stress in rats, 300

Obsessive-compulsive disorder
and PANDAS in adults, 807
and serotonin receptor gene promoter polymorphism in women, 385
therapy affecting whole blood serotonin changes, 360
Olanzapine
compared to clozapine in schizophrenia, 52
consistency compared to placebos in trials, 64
Opioid antagonists
naltrexone in pathological gambling, 914
Oppositional defiant disorder
comorbidity with pediatric bipolar disorder, 1062
Outcome assessment
long-term outcome of schizophrenic volunteers receiving ketamine, 869
Oxygen
reactive oxygen species produced in fibroblasts by light therapy, 464

P3 amplitude
in major personality traits, 922
N1 and P300 abnormalities in schizophrenia and epilepsy, 848
N2/P3 complex in schizophrenia, 832
relation to amygdala volume in offspring at risk for alcoholism, 894
PANDAS
and adult-onset obsessive-compulsive disorder, 807
Panic disorder
familial, and respiratory sensitivity to CO_2, 582
and irregular breathing patterns in patients, 588
physiologic instability in, 596
sighing in, 588, 606
Paroxetine
in mood disorders of children and adolescents, 1083
and whole blood serotonin changes in obsessive-compulsive disorder, 360

Personality traits
auditory P3 amplitude in, 922
PET studies
cerebral metabolism in bipolar disorder, 97
cholinergic therapy evaluation in Alzheimer disease, 211
clonidine affecting neural networks in depression, 317
cortical activity patterns in Alzheimer disease, 426
euphoria related to ventral striatal dopamine release, 81
neural correlates of maternal separation in monkeys, 146
nicotine affecting regional cerebral blood flow, 906
nicotinic receptors in Alzheimer disease, 200
risperidon and haloperidol affecting regional cerebral blood flow, 704
vesicular monoamine transporter binding sites in bipolar disorder and schizophrenia, 110
Phenelzine
affecting locus coeruleus electrophysiology, 117
Phospholipid metabolism
and *myo*-inositol affecting rat brain plasmalogen, 444
Physostigmine
in allosteric sensitization of nicotinic receptors, 279
Placebo responses
and consistency of antipsychotics in trials, 64
and ethical use of placebos in clinical trials, 887
in women and men with major depression, 158
Planum temporale
dimensions in schizophrenia with auditory hallucinations, 685
Polysomnography
in monozygotic narcoleptic twins, 943
and premorbid signs in depressed adolescents, 930
Posterior fossa
development in velocardiofacial syndrome, 540
Postmortem studies
neuropathology of cognitive impairment in depression, 130
prefrontal cortex cellular architecture in bipolar disorder, 741
suicide and Alzheimer's pathology, 137
Posttraumatic stress disorder
and complex insomnia in crime victims, 948
and cortisol response to dexamethasone–CRH test, 410
vagal modulation of mental challenge in, 637
Prefrontal cortex
N-acetylaspartate levels affected by antipsychotic agents, 39
cellular architecture in bipolar disorder, 741
dopamine levels
in conditioned fear stress in rats, 300
and early gene expression affected by xanomeline, 704
measurement of distance from scalp TMS coil, 454
neural correlates of maternal separation in monkeys, 146
neurokinin-1 receptors in schizophrenia, 523
noradrenergic dysfunction in depression, 317
Pregnancy
rubella in, and schizophrenia development in offspring, 473
Premenstrual dysphoric disorder
allopregnanolone levels in, 788
Premorbid abnormalities
polysomnographic signs in depressed adolescents, 930
in schizophrenia, 473
Prevention programs
for adults at risk for depression, 1101
and assessment of suicidal behavior in children, 1055
for children of depressed parents, 1101
Psychiatry
and diagnosis of mood disorders in children, 973
Psychotherapy
interventions in childhood and adolescent depression, 1091
Psychotic symptoms
relation to brain volumes in high-risk subjects, 811
Pupil dilation
in sustained processing of information in depression, 624

Quetiapine
consistency compared to placebos in trials, 64

Research
on children with mood disorders, ethical issues in, 1015
clinical outcomes after cocaine infusions in, 553
long-term outcome of schizophrenic volunteers receiving ketamine, 869
placebos and paradoxes in, 887
and vote-count review of studies, 161–corr
Respiration
irregularity in panic disorder patients, 588, 596, 606
sensitivity to CO_2 in familial panic disorder, 582
sleep-disordered breathing in posttraumatic stress syndrome, 948
Risk studies
for alcoholism
amygdala volume in offspring, 894
males with auditory P3a deficits, 726
for depression in childhood, 1101
for families with comorbid depression and anxiety, 1071
for schizophrenia, brain structural abnormalities in, 811
for suicidal behavior of children and adolescents, 1055
for suicide, and neuropathology in Alzheimer disease, 137
Risperidone
affecting regional cerebral blood flow, 704
consistency compared to placebos in trials, 64
Rivastigmine
in allosteric sensitization of nicotinic receptors, 279
RJR-2403
affecting learning and memory, 268
mRNA
expression in responses to MK-801 after neonatal hippocampal lesions, 528
Rubella
prenatal, and schizophrenia development, 473
Rumination
and information processing in depression, 624

Schizophrenia
N-acetylaspartate levels in brain affected by antipsychotic agents, 39
in adolescents, hippocampal volume changes in, 824
brain structure in high-risk subjects, 811
and cerebral symmetries in auditory hallucinations, 685

cognitive neuroscience research in, 374
consistency of antipsychotics compared to placebos, 64
dysregulated behavior in, 71
effects of nicotine in, 258
event-related potentials compared to epilepsy patients, 848
and fatty acids in erythrocytes, 510
first episodes of, brain morphology in, 487
hemispheric asymmetry of auditory processing in, 694
increased neurokinin-1 receptors in, 523
and long-term outcome of patients receiving ketamine, 869
midbrain morphology in, 13
negative symptoms in, estrogen replacement therapy affecting, 47
olanzapine compared to clozapine in, 52
and prenetal rubella, 473
reduced cerebellar vermis volume in, 20
risperidon and haloperidol affecting cerebral blood flow in, 704
tandospirone affecting memory in, 861
thalamic size in, 28
tonal and phonetic event-related potentials in, 832
vesicular monoamine transporter binding sites in, 110
xanomeline affecting dopamine levels and early gene expression in prefrontal cortex, 704
Serotonin
brain transporters in bulimia nervosa, 326
receptor 1A agonist affecting memory in schizophrenia, 861
receptor gene promoter polymorphism and obsessive-compulsive disorder in women, 385
receptors affecting impulse control, 557
reuptake inhibitors
effectiveness in depressed children and adolescents, 980
fluoxetine in anorexia nervosa, 644
hemispheric asymmetry affecting responses to, 416
in mood disorders of children and adolescents, 1083
and whole blood serotonin changes in obsessive-compulsive disorder, 360
stress-induced hyperthermia in serotonin 1A receptor knockout mice, 569
and vesicular monoamine transporter binding sites in bipolar disorder and schizophrenia, 110
whole blood changes affected by therapy in obsessive-compulsive disorder, 360
Sertraline
affecting locus coeruleus electrophysiology, 117
Sighing
in patients with panic disorder, 588, 606
Sleep
complex insomnia in crime victims, 948
in depressed children and adolescents, 980
premorbid polysomnographic signs in, 930
in monozygotic narcoleptic twins, 943
Smoking
association with Alzheimer disease, 194
and nicotine affecting regional cerebral blood flow, 906
SPECT studies
in bulimia nervosa, 326
Spinophilin
haloperidol affecting, 1
Sterotyped behavior
in autism, cerebellar role in, 655
Streptococcal infections
and adult-onset obsessive-compulsive disorder, 807
Stress
and allopregnanlone levels in premenstrual dysphoric disorder, 788
and hyperthermia in serotonin 1A receptor knockout mice, 569
and locus coeruleus activation by corticotropin-releasing hormone, 351
and neural correlates of maternal separation in monkeys, 146
neurobiologic effects of early childhood trauma, 1023
and time course of behavioral depression, 763
Striatum
nicotinic receptor abnormalities in Alzheimer disease, 175
ventral striatal dopamine release related to euphoria, 81
Substantia nigra
pars compacta affected by drugs in attention-deficit/hyperactivity disorder, 340
Suicidal behavior
diagnosis in children and adolescents, 1055
Suicide
and Alzheimer's pathology, 137
and tryptophan hydroxylase polymorphism in affective disorders, 405
Sylvian fissure
dimensions in schizophrenia with auditory hallucinations, 685
Synaptophysin
haloperidol affecting, 1

Tachykinins
neurokinin-1 receptors in schizophrenia, 523
Tacrine
as cholinesterase inhibitor, 279
Tandospirone
affecting memory in schizophrenia, 861
Thalamus
nicotinic receptor abnormalities in Alzheimer disease, 175
size in schizophrenia, 28
Thyroid hormones
alterations in depressed children and adolescents, 980
Tricyclic antidepressants
effectiveness in children and adolescents, 980
trkA receptor
binding by nerve growth factor, 185
Tryptophan hydroxylase
polymorphism in affective disorders with suicidal behavior, 405
Twins
monozygotic pairs incompletely concordant for narcolepsy, 943

Vagal tone
and heart rate in challenge test in posttraumatic stress disorder, 637

Velocardiofacial syndrome
posterior fossa development in, 540
white matter reductions in, 677
Venlafaxine
in mood disorders of children and adolescents, 1082
Ventricles, cerebral
morphology in first episode schizophrenia, 487
Vermis of cerebellum
reduced volume in schizophrenia, 20
Vesicular transporters
acetylcholine in Alzheimer disease, 211
monoamine binding sites in bipolar disorder and schizophrenia, 110
Visual event-related potentials
relation to amygdala volume in offspring at risk for alcoholism, 894
Volumetric studies
amygdala volume in offspring at risk for alcoholism, 894
brain structure in high-risk subjects, 811
cerebellar vermis volume in schizophrenia, 20
thalamus size in schizophrenia, 28

WAY-100635
effects in serotonin 1A receptor knockout mice, 569
White matter
reductions in velocardiofacial syndrome, 677
Withdrawal
and leptin as modulator of alcohol craving, 782
Women
allopregnanlone levels in premenstrual dysphoric disorder, 788
estrogen replacement therapy affecting negative symptoms in schizophrenia, 47
glucocorticoid production in Alzheimer disease, 546
serotonin receptor gene promoter polymorphism in obsessive-compulsive disorder, 385
vasoconstrictive effects of cocaine in menstrual cycle phases, 774

Xanomeline
affecting dopamine levels and early gene expression in prefrontal cortex, 704

zif/268
expression in prefrontal cortex affected by xanomeline, 704